Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics
|
Glucose-6-phosphate dehydrogenase deficiency Microchapters |
|
Differentiating Glucose-6-phosphate dehydrogenase deficiency from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics |
|
FDA on Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics |
|
CDC on Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics |
|
Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics in the news |
|
Blogs on Glucose-6-phosphate dehydrogenase deficiency epidemiology and demographics |
|
Directions to Hospitals Treating Glucose-6-phosphate dehydrogenase deficiency |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Priyamvada Singh, M.D. [2]
Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.
Overview
Epidemiology and Demographics
- G6PDD is said to be the most common enzyme deficiency disease in the world, affecting approximately 400,000,000 people globally.[1]
- A side effect of this disease is that it confers protection against malaria, in particular the form of malaria caused by Plasmodium falciparum, the most deadly form of malaria.
- A similar relationship exists between malaria and sickle-cell disease. An explanation is that cells infected with the Plasmodium parasite are cleared more rapidly by the spleen. This phenomenon might give G6PD deficiency carriers an evolutionary advantage.